Blaha M, Gasova Z, Berlin G, Audzijoniene J, Griskevicius A, Dykes J, Bhuiyanova Z, Lanska M, Eich T, Vrielink H, Witt V, Seval G C, Ilhan O, Stegmayr B
Faculty Nemocnice Hradec Kralove, University Hospital Hradec Kralove, Hradec Králové, Czech Republic.
Institute of Hematology and Blood Transfusion, UHKT, Prague, Czech Republic.
Transfus Apher Sci. 2021 Oct;60(5):103172. doi: 10.1016/j.transci.2021.103172. Epub 2021 May 27.
The aim of the study was to investigate safety and if extracorporeal photopheresis (ECP) may change health criteria (HC) and quality of life (QoL).
560 patients (33 % women) were treated with ECP for a total of 13,871 procedures during a 17-years period. Mean age was 48 years (±18, range 3-81 years). Self-estimation of QoL was graded: 0 (suicidal) up to 10 (best ever) and HC: 0 (Bed ridden, ICU condition) up to 10 (athletic). Adverse events were analyzed. ANOVA and paired comparisons were performed.
Patients were treated due to graft versus host disease (GVHD, n = 317), skin lymphoma (n = 70), solid organ transplants (n = 47), skin diseases (n = 20) and other diseases (n = 106). Adverse events (AEs) were registered in 5.4 % of the first treatments and in 1.2 % of the subsequent procedures. Severe AEs were present in 0.04 % of all procedures. No patient died due to the procedure. Tingling and stitching were the most common AE. For those with GVHD an improvement was noticed within approximately 10 procedures of ECP in the severity stage, QoL (from a mean of 6.1 to 6.8, p < 0.002) and the HC (6.1 -> 6.4, p < 0.014) and improved further with added procedures.
Photopheresis is an established therapy with few side effects. The present study of soft variables indicate that GVHD shows benefits upon ECP within approximately 10 procedures in regard to the severity of mainly skin GVHD, and lower baseline levels of HC and QoL.
本研究的目的是调查体外光化学疗法（ECP）的安全性，以及它是否会改变健康标准（HC）和生活质量（QoL）。
在17年期间，共有560例患者（33%为女性）接受了ECP治疗，总共进行了13871次治疗程序。平均年龄为48岁（±18岁，范围3 - 81岁）。生活质量的自我评估分为：0（有自杀倾向）至10（有史以来最好），健康标准分为：0（卧床不起，重症监护状态）至10（运动员状态）。对不良事件进行了分析。进行了方差分析和配对比较。
患者因移植物抗宿主病（GVHD，n = 317）、皮肤淋巴瘤（n = 70）、实体器官移植（n = 47）、皮肤病（n = 20）和其他疾病（n = 106）接受治疗。在首次治疗中，5.4%的患者出现不良事件（AE），在后续治疗程序中为1.2%。严重不良事件在所有治疗程序中占0.04%。没有患者因治疗程序死亡。刺痛和针刺感是最常见的不良事件。对于患有GVHD的患者，在进行大约10次ECP治疗后，严重程度阶段、生活质量（从平均6.1提高到6.8，p < 0.002）和健康标准（6.1 -> 6.4，p < 0.014）有所改善，并随着治疗程序的增加进一步改善。
光化学疗法是一种成熟的治疗方法，副作用较少。本研究中关于软变量的结果表明，对于GVHD患者，在进行大约10次ECP治疗后，可以在主要皮肤GVHD的严重程度、较低的健康标准基线水平和生活质量方面看到益处。
